Breaking News Instant updates and real-time market news.

GILD

Gilead

$65.85

-0.49 (-0.74%)

16:26
05/20/19
05/20
16:26
05/20/19
16:26

Gilead initiated with a Neutral at Credit Suisse

Credit Suisse analyst Evan Seigerman started Gilead Sciences with a Neutral rating and $70 price target. The does not see "outsized growth" in the company's base HIV business that would drive significant upside to earnings projections. He admits, however, that a new strategic vision or acquisition could lead to multiplier expansion.

  • 31

    May

GILD Gilead
$65.85

-0.49 (-0.74%)

04/29/19
PIPR
04/29/19
NO CHANGE
Target $75
PIPR
Neutral
Gilead the 'undisputed leader' in cell therapy, says Piper Jaffray
After conducting nearly 30 hours' worth of interviews with C-level management at numerous companies, Piper Jaffray analyst Tyler Van Buren calls Gilead Sciences the "undisputed leader" of the cell therapy space. The majority of the successes and learnings from the current generation of CAR-T products is attributable to Gilead/Kite's efforts, Van Buren tells investors in a research note. Further, he expect the company's ongoing studies and collaborations to "meaningfully improve" cell product characteristics and manufacturing conditions and ultimately result in better patient outcomes. The cell therapy space is still in its infancy and there is an" enormous opportunity ahead,' says the analyst. He keeps a Neutral rating on Gilead with a $75 price target.
05/03/19
WELS
05/03/19
UPGRADE
Target $120
WELS
Outperform
Intercept upgraded to Outperform following survey of doctors at Wells Fargo
As previously reported, Wells Fargo analyst Jim Birchenough upgraded Intercept to Outperform from Market Perform, stating that his recent survey of NASH prescribing doctors following the REGENERATE study update suggests a higher expected adoption rate of obeticholic acid and a more positive view of its efficacy. He also said he views the shares as oversold with Intercept down 12.5% year-to-date. Birchenough, who also cited recent NASH study failures of liver disease leader Gilead (GILD), raised his price target on Intercept shares to $120 from $104.
05/10/19
RILY
05/10/19
NO CHANGE
Target $158
RILY
Buy
Intercept added to Alpha Generator list at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani earlier today added Intercept Pharmaceuticals (ICPT) to his firm's Alpha Generator list. The analyst sees "strong" strong fundamentals over next year and a high likelihood of FDA approval in mid-2020. Mamtani lowered his price target for Intercept to $158 from $169 and keeps a Buy rating on the shares. His new target reflects the company's recent capital raise, the removal of removing Gilead (GILD) as near-term competitor with selonsertib's recent failure, and the push out of a European launch from the second half of 2020 to Q1 of 2021.
05/13/19
JEFF
05/13/19
NO CHANGE
Target $95
JEFF
Buy
Gilead shares reflect 'undue bearish outlook,' says Jefferies
Gilead Sciences (GILD) is trading at a 10 times price-to-earnings multiple, which reflects an "undue bearish outlook," Jefferies analyst Michael Yee tells investors in a research note. He thinks the company's base HIV business growing to 2025 and then eroding is worth $60-$65 per share, and the rest of business -- HCV, filgotinib, Yescarta -- is worth $15-$20 per share. This implies the stock should be at $80-$85, says Yee. A bear case on the HIV business is $35-$40 per share, which assumes a full cliff post 2025 or GlaxoSmithKline (GSK) taking "massive" share with doublets and long-acting, adds the analyst. Yee keeps a Buy rating on Gilead with a $95 price target.

TODAY'S FREE FLY STORIES

UNP

Union Pacific

$166.97

-0.16 (-0.10%)

07:29
06/17/19
06/17
07:29
06/17/19
07:29
Downgrade
Union Pacific rating change  »

Union Pacific downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

07:27
06/17/19
06/17
07:27
06/17/19
07:27
Downgrade
LyondellBasell rating change  »

Deutsche downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCYC

Bicycle Therapeutics

$13.00

0.61 (4.92%)

07:27
06/17/19
06/17
07:27
06/17/19
07:27
Initiation
Bicycle Therapeutics initiated  »

Bicycle Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPP

WPP

$60.56

-0.24 (-0.39%)

07:27
06/17/19
06/17
07:27
06/17/19
07:27
Hot Stocks
WPP to phase out single-use plastics »

WPP announced a series of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEEV

Veeva

$164.70

-1.555 (-0.94%)

07:26
06/17/19
06/17
07:26
06/17/19
07:26
Conference/Events
Veeva management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

SYF

Synchrony

$33.95

-0.05 (-0.15%)

07:25
06/17/19
06/17
07:25
06/17/19
07:25
Hot Stocks
Synchrony reports May net charge-off rate 4.91% vs. 5.11% last month »

Reports May 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$77.76

1.385 (1.81%)

07:25
06/17/19
06/17
07:25
06/17/19
07:25
Conference/Events
Incyte to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

PSTI

Pluristem

$0.56

0.0001 (0.02%)

07:24
06/17/19
06/17
07:24
06/17/19
07:24
Hot Stocks
Pluristem presents its first proprietary serum-free cell therapy product »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

H

Hyatt

$74.68

-0.185 (-0.25%)

07:24
06/17/19
06/17
07:24
06/17/19
07:24
Hot Stocks
Hyatt announces plan for first Alila resort in Europe »

Hyatt announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TREE

LendingTree

$386.02

-1.83 (-0.47%)

07:24
06/17/19
06/17
07:24
06/17/19
07:24
Conference/Events
LendingTree management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 27

    Jun

  • 13

    Nov

TTEC

TTEC Holdings

$44.26

0.65 (1.49%)

07:23
06/17/19
06/17
07:23
06/17/19
07:23
Recommendations
TTEC Holdings analyst commentary  »

TTEC Holdings price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EB

Eventbrite

$16.00

-0.41 (-2.50%)

07:22
06/17/19
06/17
07:22
06/17/19
07:22
Initiation
Eventbrite initiated  »

Eventbrite initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSTM

Verastem

$1.39

0.125 (9.88%)

07:22
06/17/19
06/17
07:22
06/17/19
07:22
Hot Stocks
Verastem presents Copiktra clinical data at EHA »

Verastem announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STL

Sterling Bancorp

$20.36

-0.01 (-0.05%)

07:21
06/17/19
06/17
07:21
06/17/19
07:21
Conference/Events
Sterling Bancorp management to meet with Sandler ONeill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

TC

TuanChe

$2.96

0.065 (2.25%)

07:21
06/17/19
06/17
07:21
06/17/19
07:21
Hot Stocks
TuanChe announces up to $20M share repurchase program »

TuanChe announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THO

Thor Industries

$54.30

-0.01 (-0.02%)

, UNFI

United Natural Foods

$10.28

-0.51 (-4.73%)

07:20
06/17/19
06/17
07:20
06/17/19
07:20
Recommendations
Thor Industries, United Natural Foods analyst commentary  »

Citi lowers price targets…

THO

Thor Industries

$54.30

-0.01 (-0.02%)

UNFI

United Natural Foods

$10.28

-0.51 (-4.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

AYX

Alteryx

$104.23

2.08 (2.04%)

07:19
06/17/19
06/17
07:19
06/17/19
07:19
Recommendations
Alteryx analyst commentary  »

Alteryx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRCL

Stericycle

$45.24

-0.41 (-0.90%)

07:19
06/17/19
06/17
07:19
06/17/19
07:19
Conference/Events
Stericycle management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 21

    Aug

BWEN

Broadwind Energy

$2.17

0.02 (0.93%)

07:18
06/17/19
06/17
07:18
06/17/19
07:18
Hot Stocks
Broadwind Energy announces $29M of new tower orders »

Broadwind Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$8.24

-0.37 (-4.30%)

07:17
06/17/19
06/17
07:17
06/17/19
07:17
Recommendations
Teva analyst commentary  »

Citi removes Teva from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REVG

REV Group

$12.99

-0.555 (-4.10%)

07:17
06/17/19
06/17
07:17
06/17/19
07:17
Recommendations
REV Group analyst commentary  »

REV Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIXX

Homology Medicines

$18.56

0.16 (0.87%)

07:16
06/17/19
06/17
07:16
06/17/19
07:16
Hot Stocks
Homology Medicines says single dose HMI-102 resulted in long-term PKU correction »

Homology Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$33.01

0.08 (0.24%)

07:15
06/17/19
06/17
07:15
06/17/19
07:15
Conference/Events
Synovus management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

ARRY

Array BioPharma

$29.59

0.17 (0.58%)

, PFE

Pfizer

$42.75

0.24 (0.56%)

07:14
06/17/19
06/17
07:14
06/17/19
07:14
Hot Stocks
Breaking Hot Stocks news story on Array BioPharma, Pfizer »

Array BioPharma up 59% to…

ARRY

Array BioPharma

$29.59

0.17 (0.58%)

PFE

Pfizer

$42.75

0.24 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 16

    Sep

ALNY

Alnylam

$70.04

-1.15 (-1.62%)

07:14
06/17/19
06/17
07:14
06/17/19
07:14
Hot Stocks
Alnylam announces lumasiran results, full patient enrollment in ILLUMINATE-A, »

Alnylam announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.